NDA 018163 · Specgx LLC
Restoril
Temazepam · Oral · Benzodiazepine
NovelLast checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Feb 27, 1981
Approved uses
3
Original approval plus efficacy supplements
Registered trials
9
3 Phase 3, 0 recruiting
FAERS reports
37,909
28,415 serious, 7,674 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation ( see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including temazepam capsules, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing...
What it is approved for
From the label in effect Oct 6, 2026.
INDICATIONS AND USAGE Temazepam Capsules USP are indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that Temazepam Capsules USP should be used for short periods of time (7 to 10 days). The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 25, 1991 Supplement 11 · Efficacy
- Oct 25, 1991 Supplement 22 · Efficacy
- Feb 27, 1981 Original approval · Type 1 - New Molecular Entity Other Important Information from FDA
4 products under this application
- RESTORIL · TEMAZEPAM 22.5MG · CAPSULE, ORAL · Prescription · TE AB
- RESTORIL · TEMAZEPAM 30MG · CAPSULE, ORAL · Prescription · TE AB
- RESTORIL · TEMAZEPAM 7.5MG · CAPSULE, ORAL · Prescription · TE AB
- RESTORIL · TEMAZEPAM 15MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Temazepam" as an intervention, any sponsor and status, largest first.
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Trial to Compare Femoral Nerve Block With Local Anaesthetic Injection for Post-operative Pain After Knee Replacement.Pivotal-lookingCompleted
Royal Devon and Exeter NHS Foundation TrustAcademic, hospital or other
NCT02288923 · 199 participants · Start Mar 2015 · Primary completion Jul 1, 2018
Drug: Pre-medication; Intra-operative medication and 3 more · For: Arthritis Knee
Sites: Exeter, United Kingdom
- A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)Pivotal-lookingCompleted
AO GENERIUMIndustry
NCT04679103 · 50 participants · Start May 3, 2018 · Primary completion Apr 20, 2020
Drug: Eculizumab (JSC GENERIUM, Russia) · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Chelyabinsk, Russia; Kirov, Russia; Saint Petersburg, Russia · 9 sites in all
Duke UniversityAcademic, hospital or other
NCT00465972 · 44 participants · Start Mar 2007 · Primary completion Aug 2010
Drug: Doxepin; Temazepam and 1 more · For: HIV Infections; Insomnia
Sites: Durham, North Carolina
Duke UniversityAcademic, hospital or other
NCT02153788 · 44 participants · Start Sep 2009 · Primary completion Sep 2010
Drug: Temazepam; Placebo · For: Insomnia
Massachusetts General HospitalAcademic, hospital or other
NCT01519544 · 34 participants · Start Mar 2012 · Primary completion Jul 2012
Drug: Temazepam; Acetazolamide · For: High-altitude Sleep Disturbance
Sites: Manang, Nepal
Johns Hopkins UniversityAcademic, hospital or other
NCT02033707 · 20 participants · Start Apr 2014 · Primary completion Feb 2019
Drug: Hallucinogens and psychoactive substances · For: Healthy
Sites: Baltimore, Maryland
- Study to Investigate the Effects of Melatonin, Temazepam & Zolpidem on Sleep EEG in Men and WomenCompleted
University of SurreyAcademic, hospital or other
NCT00940550 · 16 participants · Start Jul 2009 · Primary completion Aug 2009
Drug: Prolonged-release melatonin; Temazepam and 2 more · For: Insomnia
Sites: Guildford, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue2,856
- drug ineffective2,480
- nausea2,454
- pain2,332
- headache2,331
- toxicity to various agents2,306
- diarrhoea1,841
- dyspnoea1,792
- insomnia1,707
- death1,701
- dizziness1,691
- off label use1,683
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 841 |
| 2005 | 965 |
| 2006 | 1,079 |
| 2007 | 922 |
| 2008 | 924 |
| 2009 | 1,231 |
| 2010 | 1,588 |
| 2011 | 1,536 |
| 2012 | 1,790 |
| 2013 | 1,473 |
| 2014 | 1,664 |
| 2015 | 2,614 |
| 2016 | 2,850 |
| 2017 | 2,573 |
| 2018 | 2,626 |
| 2019 | 2,570 |
| 2020 | 2,378 |
| 2021 | 1,862 |
| 2022 | 1,352 |
| 2023 | 1,427 |
| 2024 | 1,528 |
| 2025 | 1,173 |
| 2026 | 941 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Restoril (Temazepam)
2024 spending
$713K
Beneficiaries
105
470 claims
Per beneficiary
$6,790
$30.62 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,423,306 |
| 2021 | $1,385,243 |
| 2022 | $1,209,060 |
| 2023 | $983,605 |
| 2024 | $712,925 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial.
Fung CH, Alessi C, Martin JL, et al. · JAMA Intern Med 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Post-traumatic stress disorder.
Bisson JI · BMJ Clin Evid 2007 · Systematic Review
- Post-traumatic stress disorder.
Bisson JI · BMJ Clin Evid 2010 · Systematic Review
- Insomnia in the elderly.
Montgomery P, Lilly J · BMJ Clin Evid 2007 · Systematic Review
- Adverse events of pharmacological interventions for insomnia disorder in adults: a systematic review and network meta-analysis.
Lu C, Geng Y, Guan X, et al. · Front Psychiatry 2025 · Systematic Review
- One man's poison.
Hunter A · Lancet 1978 · Clinical Trial, Comparative Study
Sponsor: Specgx LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.